Streamlined.financeStreamlined.finance
MarketsFind Stocks

Becton, Dickinson and Company

NYSE

Market Cap.

69.44B

Avg. Volume

1.32M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Becton, Dickinson and Company

Becton, Dickinson and Company News

Becton, Dickinson and Company Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareMedical - Instruments & Supplies
bd.com

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Becton, Dickinson and Company Earnings & Revenue

Becton, Dickinson and Company Financials

Table Compare

Compare BDX metrics with:

   

Earnings & Growth

BDX

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

BDX

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

BDX

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

BDX

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Becton, Dickinson and Company Income

Becton, Dickinson and Company Balance Sheet

Becton, Dickinson and Company Cash Flow

Becton, Dickinson and Company Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityNeutral
Return on AssetsBuy
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioSell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Becton, Dickinson and Company Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

3.8000

Payment DateDividendFrequency
2024-09-300.95Quarterly
2024-06-280.95Quarterly
2024-03-290.95Quarterly
2023-12-290.95Quarterly

Becton, Dickinson and Company Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Becton, Dickinson and Company Executives

NameRole
Mr. Thomas E. Polen Jr.President, Chief Executive Officer & Chairman
Ms. Shana Carol NealExecutive Vice President & Chief People Officer
Mr. Michael GarrisonExecutive Vice President & President of Medical segment
Mr. Christopher J. DelOreficeExecutive Vice President & Chief Financial Officer
Ms. Elizabeth McCombsExecutive Vice President & Chief Technology Officer
NameRoleGenderDate of BirthPay
Mr. Thomas E. Polen Jr.President, Chief Executive Officer & ChairmanMale19733.46M
Ms. Shana Carol NealExecutive Vice President & Chief People OfficerFemale19661.79M
Mr. Michael GarrisonExecutive Vice President & President of Medical segmentMale19701.73M
Mr. Christopher J. DelOreficeExecutive Vice President & Chief Financial OfficerMale19711.6M
Ms. Elizabeth McCombsExecutive Vice President & Chief Technology OfficerFemale1976

--

Becton, Dickinson and Company Insider Trades

Date7 Sep
NameDelOrefice Christopher
RoleEVP & Chief Financial Officer
TransactionDisposed
TypeF-InKind
Shares466
Date1 Sep
NameByrd Richard
RoleEVP & President Interventional
TransactionDisposed
TypeF-InKind
Shares216
Date1 Sep
NameDelOrefice Christopher
RoleEVP & Chief Financial Officer
TransactionDisposed
TypeF-InKind
Shares254
Date20 Aug
NameFeld Michael
RoleEVP & President, Life Sciences
TransactionAcquired
TypeA-Award
Shares6637
Date20 Aug
NameFeld Michael
RoleEVP & President, Life Sciences
TransactionDisposed
Type
Shares0
DateNameRoleTransactionTypeShares
7 SepDelOrefice ChristopherEVP & Chief Financial OfficerDisposedF-InKind466
1 SepByrd RichardEVP & President InterventionalDisposedF-InKind216
1 SepDelOrefice ChristopherEVP & Chief Financial OfficerDisposedF-InKind254
20 AugFeld MichaelEVP & President, Life SciencesAcquiredA-Award6637
20 AugFeld MichaelEVP & President, Life SciencesDisposed0

Discover More

Streamlined Academy

Becton, Dickinson and Company

NYSE

Market Cap.

69.44B

Avg. Volume

1.32M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Becton, Dickinson and Company News

Becton, Dickinson and Company Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Becton, Dickinson and Company Earnings & Revenue

Becton, Dickinson and Company Income

Becton, Dickinson and Company Balance Sheet

Becton, Dickinson and Company Cash Flow

Becton, Dickinson and Company Financials Over Time

Becton, Dickinson and Company Executives

NameRole
Mr. Thomas E. Polen Jr.President, Chief Executive Officer & Chairman
Ms. Shana Carol NealExecutive Vice President & Chief People Officer
Mr. Michael GarrisonExecutive Vice President & President of Medical segment
Mr. Christopher J. DelOreficeExecutive Vice President & Chief Financial Officer
Ms. Elizabeth McCombsExecutive Vice President & Chief Technology Officer
NameRoleGenderDate of BirthPay
Mr. Thomas E. Polen Jr.President, Chief Executive Officer & ChairmanMale19733.46M
Ms. Shana Carol NealExecutive Vice President & Chief People OfficerFemale19661.79M
Mr. Michael GarrisonExecutive Vice President & President of Medical segmentMale19701.73M
Mr. Christopher J. DelOreficeExecutive Vice President & Chief Financial OfficerMale19711.6M
Ms. Elizabeth McCombsExecutive Vice President & Chief Technology OfficerFemale1976

--

Becton, Dickinson and Company Insider Trades

Date7 Sep
NameDelOrefice Christopher
RoleEVP & Chief Financial Officer
TransactionDisposed
TypeF-InKind
Shares466
Date1 Sep
NameByrd Richard
RoleEVP & President Interventional
TransactionDisposed
TypeF-InKind
Shares216
Date1 Sep
NameDelOrefice Christopher
RoleEVP & Chief Financial Officer
TransactionDisposed
TypeF-InKind
Shares254
Date20 Aug
NameFeld Michael
RoleEVP & President, Life Sciences
TransactionAcquired
TypeA-Award
Shares6637
Date20 Aug
NameFeld Michael
RoleEVP & President, Life Sciences
TransactionDisposed
Type
Shares0
DateNameRoleTransactionTypeShares
7 SepDelOrefice ChristopherEVP & Chief Financial OfficerDisposedF-InKind466
1 SepByrd RichardEVP & President InterventionalDisposedF-InKind216
1 SepDelOrefice ChristopherEVP & Chief Financial OfficerDisposedF-InKind254
20 AugFeld MichaelEVP & President, Life SciencesAcquiredA-Award6637
20 AugFeld MichaelEVP & President, Life SciencesDisposed0

Streamlined Academy

Website screenshot
HealthcareMedical - Instruments & Supplies
bd.com

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Becton, Dickinson and Company

Becton, Dickinson and Company Financials

Table Compare

Compare BDX metrics with:

   

Earnings & Growth

BDX

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

BDX

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

BDX

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

BDX

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Becton, Dickinson and Company Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

3.8000

Payment DateDividendFrequency
2024-09-300.95Quarterly
2024-06-280.95Quarterly
2024-03-290.95Quarterly
2023-12-290.95Quarterly

Becton, Dickinson and Company Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityNeutral
Return on AssetsBuy
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioSell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)